LifeVantage
Provides nutrigenomic wellness products to customers and independent consultants.
Something off on this page? Send us feedback.
Profile
Develops nutrigenomic health-and-wellness products rooted in the Protandim line and expanded with LoveBiome’s microbiome-health operating assets. Products are provided to customers and independent consultants, who participate in a commission-based direct-sales opportunity.
Originating with Protandim, the portfolio now includes nutrigenomic health-and-wellness products and LoveBiome’s microbiome-health operating assets. The acquisition added microbiome-health products and personnel to the platform and expanded its consultant network. Products are provided to customers and independent consultants, who participate in a commission-based direct-sales opportunity.
Operations extend across the Americas, Asia-Pacific, and Europe. The business shifted from retail to direct sales after determining its science-heavy product required explanation, making consultant-led distribution central to the model. Product formulation, labeling, advertising, and related claims remain subject to FDA, FTC, and comparable laws.
Company facts
Key statistics
Year to date +5.0% · Average volume (30d) 60.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Lake Street | Reiterate | Hold | $5 | $6 | |
| May 7, 2026 | Lake Street | Downgrade | Buy | Hold | ||
| Feb 5, 2026 | Loop Capital Markets | Target | $5 | |||
| Feb 5, 2026 | Lake Street | Target | $12 | $5 | ||
| Nov 5, 2025 | Lake Street | Target | $30 | $12 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026Q4 FY26 | $0.12 | $0.11 | −4.3% | $44.0M | $42.4M | −3.6% | −1.40% |
| May 6, 2026Q3 FY26 | $0.16 | $0.12 | −25.0% | $47.8M | $43.7M | −8.5% | −16.33% |
| Feb 4, 2026Q2 FY26 | $0.19 | $0.15 | −21.1% | $54.4M | $48.9M | −10.1% | −16.76% |
| Nov 4, 2025Q1 FY26 | $0.17 | $0.18 | +5.9% | $54.4M | $58.4M | +7.4% | +4.43% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $58.4M | $55.1M | $47.6M | $48.9M | $43.7M | $42.4M | |
| Gross profit | $47.3M | $44.0M | $37.8M | $36.2M | $34.5M | $33.0M | |
| Operating income | $4.1M | $2.1M | $2.3M | $487.0K | $1.7M | $1.7M | |
| Net income | $3.5M | $2.0M | $2.2M | $276.0K | $1.4M | $1.3M | |
| Diluted EPS | $0.26 | $0.15 | $0.17 | $0.02 | $0.11 | $0.10 | |
| Gross margin | 81.0% | 79.9% | 79.5% | 74.0% | 79.0% | 78.0% | |
| Operating margin | 6.9% | 3.9% | 4.8% | 1.0% | 3.8% | 3.9% |
Fiscal years (4-quarter sums)FY22 $206.4M · FY23 $213.4M · FY24 $200.2M · FY25 $228.5M · FY26 $182.6M
Revenue by product · Q4 FY26
Revenue by geography · Q4 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $14.9M · Total debt $9.9M · Total assets $62.1M · Shareholders' equity $33.6M
Dividends
Raised for 3 straight years — most recently to $0.05 from $0.045 in Jun 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 1, 2026 | Jun 1 | Jun 15 | $0.05 | raised from $0.045 |
| Mar 2, 2026 | Mar 2 | Mar 16 | $0.045 | |
| Dec 1, 2025 | Dec 1 | Dec 15 | $0.045 | |
| Sep 8, 2025 | Sep 8 | Sep 16 | $0.045 | |
| May 30, 2025 | May 30 | Jun 13 | $0.045 | raised from $0.04 |
| Mar 3, 2025 | Mar 3 | Mar 17 | $0.04 | |
| Dec 2, 2024 | Dec 2 | Dec 16 | $0.04 | |
| Sep 9, 2024 | Sep 9 | Sep 17 | $0.04 |
Ownership
Shares outstanding 12.62M · Float 10.48M · 83.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| The Capital Management Corporation | 1.88M | 14.90% | 13G | Jul 6, 2026 |
| Steven R. Fife · director, officer: President and CEO | 735.5K | 5.83% | Form 4 | Apr 3, 2026 |
| Renaissance Technologies LLC | 669.4K | 5.31% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 429.2K | 3.40% | 13F | Aug 13, 2026 |
| Terrence Moorehead · director, officer: President and CEO | 308.6K | 2.45% | Form 4 | Aug 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Darwin Lewis | director | +705 | $8.60 |
| Jun 3, 2026 | Michael A. Beindorff | director | −10,000 | $8.55 |
| Mar 16, 2026 | Darwin Lewis | director | +1,055 | $5.23 |
| Feb 26, 2026 | Judd Dayton | director | +4,600 | $4.58 |
| Feb 27, 2026 | Judd Dayton | director | +18,097 | $4.63 |
Peers
- Herbalife
Global direct-selling nutrition platform with a Member network
- USANA Health Sciences
Science-based supplements, foods and personal care sold direct
- Nu Skin
Beauty and wellness products sold through person-to-person channels
- Nature's Sunshine Products
Nutritional and personal-care products sold through consultants
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LifeVantage | $6.26 | −1.11% | $80.2M | 15.9 | 17.3 | 0.4 | −23.1% |
| Herbalife | $12.50 | +0.52% | $1.29B | 8.0 | 4.7 | 0.2 | +5.4% |
| USANA Health Sciences | $14.04 | +0.07% | $259.2M | — | 13.8 | 0.3 | −5.3% |
| Nu Skin | $4.85 | +0.21% | $235.5M | — | 5.0 | 0.2 | −17.1% |
| Nature's Sunshine Products | $14.21 | −0.07% | $249.9M | 14.1 | 13.2 | 0.5 | +2.0% |
| Median | 11.0 | 9.1 | 0.3 | −1.7% |